{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:14:25Z","timestamp":1789780465547,"version":"4.0.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":179,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001529","name":"Waikato Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype, has a median overall survival of 11-14 months despite standard treatment. Ketogenic metabolic interventions that lower the glucose ketone index (GKI) may improve outcomes. We evaluated the feasibility, tolerability, and potential clinical benefit of integrating standard treatment with an intensive multimodal metabolic therapy program (MTP) in newly diagnosed IDH-wildtype GBM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients received standard chemoradiation and adjuvant chemotherapy alongside an MTP comprising prolonged fasting, time-restricted feeding, and a ketogenic diet. The primary outcome was the proportion sustaining a mean daily GKI \u22646 during chemoradiation. Secondary outcomes included GKI control throughout chemotherapy, body weight, body mass index, adverse events, performance, exercise, quality of life, and survival, compared with contemporary controls using unadjusted hazard ratios (HRs) and 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 32 eligible patients, 18 commenced chemoradiation with the MTP (intention-to-treat), and 15 completed it (per-protocol). In the intention-to-treat population, 15 of 18 patients (83%) sustained a mean daily GKI \u22646 during chemoradiation. Among per-protocol patients, the GKI was 1.88\u2009\u00b1\u20090.56 during chemoradiation and 2.53\u2009\u00b1\u20090.86 throughout chemotherapy. Intentional weight loss averaged 17%, normalizing body mass index. MTP-related adverse events were mild or moderate. Exercise activity and quality of life improved. Median overall survival was 21.5 months versus 14.7 months in controls (HR\u2009=\u20090.42, 95% CI 0.18-0.97, P\u2009=\u2009.027), with 3-year survival of 27% versus 7%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intensive multimodal metabolic therapy was feasible, well-tolerated, and associated with improved exercise activity, quality of life, and survival outcomes, including higher 3-year survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag165","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:50:48Z","timestamp":1782751848000},"source":"Crossref","is-referenced-by-count":1,"title":["Intensive multimodal ketogenic metabolic therapy in glioblastoma: A clinical trial"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-7766","authenticated-orcid":false,"given":"Matthew C L","family":"Phillips","sequence":"first","affiliation":[{"name":"Department of Neurology, Waikato Hospital , Hamilton,","place":["New Zealand"]},{"name":"Department of Medicine, University of Auckland , Auckland,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Thotathil","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Waikato Hospital , Hamilton,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Azri Bin","family":"Haji Mohd Yasin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Waikato Hospital , Hamilton,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"de Groot","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Waikato Hospital , Hamilton,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Waikato Hospital , Hamilton,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Kuper-Hommel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Waikato Hospital , Hamilton,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Ann","family":"Creagh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Waikato Hospital , Hamilton,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Wellington Hospital , Wellington,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Wellington Hospital , Wellington,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariska","family":"van Essen","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Wellington Hospital , Wellington,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouzia","family":"Ziad","sequence":"additional","affiliation":[{"name":"Department of Pathology, Waikato Hospital , Hamilton,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben G","family":"Moon","sequence":"additional","affiliation":[{"name":"Midland MRI, Waikato Hospital , Hamilton,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Frampton","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago , Christchurch,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B","family":"Jameson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Waikato Hospital , Hamilton,","place":["New Zealand"]},{"name":"Waikato Clinical Campus, University of Auckland , Hamilton,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"2026080302262370600_vdag165-B1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other Central nervous system tumors diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026080302262370600_vdag165-B2","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026080302262370600_vdag165-B3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080302262370600_vdag165-B4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026080302262370600_vdag165-B5","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1158\/1078-0432.CCR-09-0715","article-title":"IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas","volume":"15","author":"Nobusawa","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026080302262370600_vdag165-B6","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1200\/JCO.2009.21.9832","article-title":"Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas","volume":"27","author":"Sanson","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026080302262370600_vdag165-B7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/s41379-021-00778-x","article-title":"Molecular landscape of IDH-mutant primary astrocytoma grade IV\/glioblastomas","volume":"34","author":"Wong","year":"2021","journal-title":"Mod Pathol"},{"key":"2026080302262370600_vdag165-B8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"2026080302262370600_vdag165-B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1743-7075-2-30","article-title":"Targeting energy metabolism in brain cancer: review and hypothesis","volume":"2","author":"Seyfried","year":"2005","journal-title":"Nutr Metab (Lond)"},{"key":"2026080302262370600_vdag165-B10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/carcin\/bgt480","article-title":"Cancer as a metabolic disease: implications for novel therapeutics","volume":"35","author":"Seyfried","year":"2014","journal-title":"Carcinogenesis"},{"key":"2026080302262370600_vdag165-B11","doi-asserted-by":"publisher","first-page":"1759091418818261","DOI":"10.1177\/1759091418818261","article-title":"Mitochondrial substrate-level phosphorylation as energy source for glioblastoma: review and hypothesis","volume":"10","author":"Chinopoulos","year":"2018","journal-title":"ASN Neuro"},{"key":"2026080302262370600_vdag165-B12","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.3390\/cancers3033242","article-title":"Aberrant signaling pathways in glioma","volume":"3","author":"Nakada","year":"2011","journal-title":"Cancers"},{"key":"2026080302262370600_vdag165-B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01913123.2023.2175942","article-title":"Comparative survey of mitochondrial ultrastructure in IDH1-mutant astrocytoma and IDH1-wildtype glioblastoma (GBM)","volume":"47","author":"Maraqah","year":"2023","journal-title":"Ultrastruct Pathol"},{"key":"2026080302262370600_vdag165-B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/jmicro\/dfm038","article-title":"Ultrastructural mitochondrial pathology in human astrocytic tumors: potentials implications pro-therapeutics strategies","volume":"57","author":"Arismendi-Morillo","year":"2008","journal-title":"J Electron Microsc"},{"key":"2026080302262370600_vdag165-B15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/glia.22621","article-title":"Alterations of oxidative phosphorylation complexes in astrocytomas","volume":"62","author":"Feichtinger","year":"2014","journal-title":"Glia"},{"key":"2026080302262370600_vdag165-B16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/s12916-024-03775-4","article-title":"Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma","volume":"22","author":"Duraj","year":"2024","journal-title":"BMC Med"},{"key":"2026080302262370600_vdag165-B17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.critrevonc.2017.02.016","article-title":"Role of ketogenic metabolic therapy in malignant glioma: a systematic review","volume":"112","author":"Winter","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026080302262370600_vdag165-B18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12986-015-0009-2","article-title":"The glucose ketone index calculator: a simple tool to monitor therapeutic efficacy for metabolic management of brain cancer","volume":"12","author":"Meidenbauer","year":"2015","journal-title":"Nutr Metab (Lond)"},{"key":"2026080302262370600_vdag165-B19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13046-019-1189-9","article-title":"Effects of short-term fasting on cancer treatment","volume":"38","author":"de Groot","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2026080302262370600_vdag165-B20","doi-asserted-by":"publisher","first-page":"21064","DOI":"10.1038\/s41598-025-06675-6","article-title":"A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma","volume":"15","author":"Amaral","year":"2025","journal-title":"Sci Rep"},{"key":"2026080302262370600_vdag165-B21","doi-asserted-by":"publisher","first-page":"1489812","DOI":"10.3389\/fnut.2024.1489812","article-title":"Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study","volume":"11","author":"Kiryttopoulos","year":"2024","journal-title":"Front Nutr"},{"key":"2026080302262370600_vdag165-B22","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1111\/cas.15492","article-title":"Effect of fasting on cancer: a narrative review of scientific evidence","volume":"113","author":"Tiwari","year":"2022","journal-title":"Cancer Sci"},{"key":"2026080302262370600_vdag165-B23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3390\/jpm14090929","article-title":"Systematic review and clinical insights: the role of the ketogenic diet in managing glioblastoma in cancer neuroscience","volume":"14","author":"Valerio","year":"2024","journal-title":"J Pers Med"},{"key":"2026080302262370600_vdag165-B24","doi-asserted-by":"publisher","first-page":"4496734","DOI":"10.1155\/2022\/4496734","article-title":"Feasibility and safety of a combined metabolic strategy in glioblastoma multiforme: a prospective case series","volume":"2022","author":"Phillips","year":"2022","journal-title":"J Oncol"},{"key":"2026080302262370600_vdag165-B25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3892\/ol.2024.14363","article-title":"Ketogenic metabolic therapy in conjunction with standard treatment for glioblastoma: a case report","volume":"27","author":"Phillips","year":"2024","journal-title":"Oncol Lett"},{"key":"2026080302262370600_vdag165-B26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2026080302262370600_vdag165-B27","first-page":"141","article-title":"A simple method to assess exercise behavior in the community","volume":"10","author":"Godin","year":"1985","journal-title":"Can J Appl Sport Sci"},{"key":"2026080302262370600_vdag165-B28","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/1097-0142(19950301)75:5<1151::AID-CNCR2820750515>3.0.CO;2-Q","article-title":"The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors","volume":"75","author":"Weitzner","year":"1995","journal-title":"Cancer"},{"key":"2026080302262370600_vdag165-B29","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080302262370600_vdag165-B30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40170-020-00230-9","article-title":"Treatment of glioblastoma multiforme with \u201cclassic\u201d 4:1 ketogenic diet total meal replacement","volume":"8","author":"Klein","year":"2020","journal-title":"Cancer Metab"},{"issue":"3","key":"2026080302262370600_vdag165-B31","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1093\/brain\/aww324","article-title":"Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels","volume":"140","author":"Klement","year":"2017","journal-title":"Brain"},{"key":"2026080302262370600_vdag165-B32","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3390\/cancers16071393","article-title":"Dexamethasone in patients with glioblastoma: a systematic review and meta-analysis","volume":"16","author":"Scheffler","year":"2024","journal-title":"Cancers"},{"key":"2026080302262370600_vdag165-B33","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1172\/JCI113450","article-title":"Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man","volume":"81","author":"Ho","year":"1988","journal-title":"J Clin Invest"},{"key":"2026080302262370600_vdag165-B34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0065-2571(72)90011-8","article-title":"Hormonal regulation of glutamine metabolism in fasting man","volume":"10","author":"Aoki","year":"1972","journal-title":"Adv Enzyme Regul"},{"key":"2026080302262370600_vdag165-B35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12986-017-0178-2","article-title":"Press-pulse: a novel therapeutic strategy for the metabolic management of cancer","volume":"14","author":"Seyfried","year":"2017","journal-title":"Nutr Metab (Lond)"},{"key":"2026080302262370600_vdag165-B36","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","article-title":"ESPEN expert group recommendations for action against cancer-related malnutrition","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr"},{"key":"2026080302262370600_vdag165-B37","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1053\/meta.2002.32037","article-title":"Body composition and hormonal responses to a carbohydrate-restricted diet","volume":"51","author":"Volek","year":"2002","journal-title":"Metabolism"},{"key":"2026080302262370600_vdag165-B38","doi-asserted-by":"publisher","first-page":"pkz054","DOI":"10.1093\/jncics\/pkz054","article-title":"Intentional weight loss and obesity-related cancer risk","volume":"3","author":"Luo","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"2026080302262370600_vdag165-B39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnut.2018.00020","article-title":"Management of glioblastoma multiforme in a patient treated with ketogenic metabolic therapy and modified standard of care: a 24-month follow-up","volume":"5","author":"Elsakka","year":"2018","journal-title":"Front Nutr"},{"key":"2026080302262370600_vdag165-B40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1743-7075-7-33","article-title":"Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case report","volume":"7","author":"Zuccoli","year":"2010","journal-title":"Nutr Metab (Lond)"},{"key":"2026080302262370600_vdag165-B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-021-03745-3","article-title":"Physical activity and exercise in adults diagnosed with primary brain cancer: a systematic review","volume":"153","author":"Sandler","year":"2021","journal-title":"J Neurooncol"},{"key":"2026080302262370600_vdag165-B42","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1470-2045(05)70432-0","article-title":"Health-related quality of life in patients with glioblastoma: a randomised controlled trial","volume":"6","author":"Taphoorn","year":"2005","journal-title":"Lancet Oncol"},{"key":"2026080302262370600_vdag165-B43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/152165401753311780","article-title":"Ketone bodies, potential therapeutic uses","volume":"51","author":"Veech","year":"2001","journal-title":"IUBMB Life"},{"key":"2026080302262370600_vdag165-B44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11060-021-03886-5","article-title":"Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG oncology RTOG 0525 and 0825","volume":"155","author":"Patil","year":"2021","journal-title":"J Neurooncol"},{"key":"2026080302262370600_vdag165-B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/noajnl\/vdaa070","article-title":"Treatment and surgical factors associated with longer-term glioblastoma survival: a national cancer database study","volume":"2","author":"Malay","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2026080302262370600_vdag165-B46","doi-asserted-by":"publisher","first-page":"11622","DOI":"10.1038\/s41598-020-68011-4","article-title":"Longer-term (\u22652 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis","volume":"10","author":"Poon","year":"2020","journal-title":"Sci Rep"},{"key":"2026080302262370600_vdag165-B47","doi-asserted-by":"publisher","first-page":"vdaf264","DOI":"10.1093\/noajnl\/vdaf264","article-title":"Ketogenic diet therapy for high-grade gliomas combined with standard treatment using an angiogenesis inhibitor: an exploratory pilot study on feasibility","volume":"8","author":"Sasayama","year":"2026","journal-title":"Neurooncol Adv"},{"key":"2026080302262370600_vdag165-B48","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11060-022-04166-6","article-title":"Ventricular entry during surgical resection is associated with intracranial leptomeningeal dissemination in glioblastoma patients","volume":"160","author":"Battista","year":"2022","journal-title":"J Neurooncol"},{"key":"2026080302262370600_vdag165-B49","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41374-021-00694-3","article-title":"Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors","volume":"102","author":"Kim","year":"2022","journal-title":"Lab Invest"},{"key":"2026080302262370600_vdag165-B50","doi-asserted-by":"publisher","first-page":"e0296523","DOI":"10.1371\/journal.pone.0296523","article-title":"Feasibility and metabolic outcomes of a well\u2011formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: the keto\u2011CARE trial","volume":"19","author":"Buga","year":"2024","journal-title":"PLoS One"},{"key":"2026080302262370600_vdag165-B51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science"},{"key":"2026080302262370600_vdag165-B52","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ijrobp.2018.08.033","article-title":"Late effects of radiation prime the brain microenvironment for accelerated tumor growth","volume":"103","author":"Duan","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag165\/68645781\/vdag165.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag165\/68645781\/vdag165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag165\/68645781\/vdag165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:26:28Z","timestamp":1785738388000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag165\/8721585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag165","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag165"}}